Peripheral T-cell Lymphoma
Conditions
Interventions
Experimental Group:Golidocitinib Combined with CMOP (Go-CMOP) Regimen
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Initial treatment; 2. Histopathological diagnosis of PTCL and no previous anti-tumor treatment; 3. Age>=18, = 50%, and there is sufficient bone marrow reserve function; 10. Good compliance with the requirements of research procedures.
Exclusion criteria
Exclusion criteria: 1. Previously treated for lymphoma, except for short-term glucocorticoids (2× ULN, alkaline phosphatase or bilirubin >1.5×ULN, creatinine >1.5×ULN; 11. Unable to comply with the agreement due to mental state or other unknown reasons such as pregnancy and breastfeeding; 12. HIV infection; If HBsAg is positive, HBVDNA should be tested, DNA-positive patients cannot be enrolled, if HBsAg is negative and HBcAb positive (regardless of HBsAb status), HBVDNA should be examined, DNA-positive patients cannot be enrolled; 13. Refractory nausea or vomiting that cannot be relieved by supportive treatment, chronic gastrointestinal disease, inability to swallow drugs or previous major bowel resection that affects adequate absorption of golixitinib; 14. Other uncontrollable medical conditions that may interfere with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Response Rate at the 3rd and 6th Courses;Safety;Overall Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Remission;Progression-Free Survival;From the first response to disease progression or death from any cause; | — |
Countries
China
Contacts
Public ContactHaigeYe
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed